MET and breast carcinoma: The resulting product 64Cu‐NOTA‐rh‐HGF was assessed by flow cytometry using human glioblastoma cell lines (U87‐MG) with moderate c‐Met expression and human breast cancer (MDA‐MB‐231) with lower (compared to U87‐MG) c‐Met expression, confirming the specific binding of the labeled HGF to c‐Met overexpressing cells.